Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease (PD-MCI-TMS)
Primary Purpose
Parkinson's Disease, Mild Cognitive Impairment
Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
TMS
Sham-TMS
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Transcranial Magnetic Stimulation
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of idiopathic Parkinson's disease any stage
- Mild Cognitive Behaviour confirmed through neuropsychological assessment
- MRI Compatibility
Exclusion Criteria:
- Alcohol-dependency
- Severe psychiatric disorder, neurological disorder, epilepsy or stroke
- General anaesthesia in the past six months
- History of cerebrovascular disorders
- Colour-blindness
Sites / Locations
- University of Calgary, Department of Clinical Neurosciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
PD-MCI, TMS
PD-MCI, Sham-TMS
Arm Description
The patient is treated with TMS stimulation according to protocol with an active coil.
The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
Outcomes
Primary Outcome Measures
TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition
Changes in one or more of the five assessed brain domains at baseline and one day after stimulation will be measured by comparing the scores for the different neuropsychological tests.
The same neuropsychological assessment one month after TMS stimulation will show, if possible changes from one day after are longer lasting and can still be seen.
Secondary Outcome Measures
Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation
MRI analysis will measure any changes in cortical thickness (mm) or other structural changes in the brain after TMS or Sham-TMS stimulation
Change in executive functioning measured as BOLD fMRI sequence
The executive task, Wisconsin Card Sorting Task, will be performed in the scanner to measure the level of activation in the basal ganglia and the prefrontal cortex via BOLD functional MRI sequence to see changes after TMS stimulation compared to baseline.
Change in levels of biomarkers of interest (alpha-synuclein and BDNF) in serum after TMS stimulation compared to baseline.
Measure the concentration of alpha-synuclein and BDNF in serum at baseline and after TMS stimulation with the Meso Scale Discovery method. These assays are highly developed ELISA assays using electrochemiluminescence.
Genotyping
Analyze DNA for following genes: COMT, DAT1, MAPT, ApoE, GBA, CHCRA4, SNCA, BDNF These genes of interest will be correlated to changes in the neuropsychological assessments.
Full Information
NCT ID
NCT03243214
First Posted
August 2, 2017
Last Updated
October 15, 2020
Sponsor
University of Calgary
Collaborators
Montreal Neurological Institute and Hospital, McGill University, Canadian Institutes of Health Research (CIHR)
1. Study Identification
Unique Protocol Identification Number
NCT03243214
Brief Title
Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease
Acronym
PD-MCI-TMS
Official Title
Effect of Excitatory Theta-Burst Transcranial Magnetic Stimulation on Cognition in Patients With Both Parkinson's Disease and Mild Cognitive Impairment and Analysis of Functional and Structural Brain Changes After Stimulation
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
October 24, 2016 (Actual)
Primary Completion Date
February 14, 2020 (Actual)
Study Completion Date
February 14, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Calgary
Collaborators
Montreal Neurological Institute and Hospital, McGill University, Canadian Institutes of Health Research (CIHR)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Parkinson's disease (PD) affects more than 100,000 Canadians and results in symptoms affecting both motor and cognitive (thinking and memory) functions. Parkinson's disease with Mild Cognitive Impairment (MCI) frequently results in development of dementia for which few treatment options exist. Transcranial Magnetic Stimulation (TMS) is used to alter activity in the outer regions of the brain and has been shown in previous studies to increase cognitive performance in patients with different disorders. This study will investigate the effectiveness of TMS as a clinical treatment for the cognitive deficits associated with Parkinson's disease. 64 male and female participants between the ages of 50 and 90 will attend eight study visits over a period of 63 to 66 days. This study is a double-blind randomized clinical trial meaning the participant will be assigned by chance to either the TMS-treatment group or the Sham-treatment group. Additionally, a combination of memory and thinking tests and Magnetic Resonance Imaging (MRI) will be used to see if there are structural and functional changes within the brain. Genotyping and blood analysis before and after treatment for different biomarkers will also be performed and these data will be compared to the TMS data. Initially, this research will increase knowledge about the effects of TMS on various brain regions. Ultimately, we will be able to determine if TMS can be used as a complementary therapy for PD to improve cognitive performance and to reduce progression into dementia.
Detailed Description
Visit 1:
Informed Consent Neuropsychological Battery
Visit 2: (1-2 days later) Blood Draw Neuropsychiatric Assessment Questionnaires Companion Questionnaire to take home UPDRS
Visit 3: (up to a week after visit 2) MRI Scan while performing Executive Task
Visit 4: (1-3 days after visit 3) TMS- or Sham-Treatment (two sessions , 20 min each, 1 hour apart)
Visit 5: (2-3 days after visit 4) Same as Visit 4
Visit 6: (2-3 days after visit 5) Same as Visit 4
Visit 7: (1 day after visit 6) Neuropsychological Battery UPDRS
Visit 8: (1 day after visit 7) MRI Scan while performing Executive Task Blood Draw
Visit 9: (1 month after visit 6) Neuropsychological Battery UPDRS
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease, Mild Cognitive Impairment
Keywords
Transcranial Magnetic Stimulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
This is a randomized double blind trial.
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
The participant and investigator do not know what treatment is applied (TMS stimulation or Sham-TMS stimulation with a different coil).
The outcomes assessor will also be blinded.
Allocation
Randomized
Enrollment
41 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PD-MCI, TMS
Arm Type
Active Comparator
Arm Description
The patient is treated with TMS stimulation according to protocol with an active coil.
Arm Title
PD-MCI, Sham-TMS
Arm Type
Sham Comparator
Arm Description
The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
Intervention Type
Device
Intervention Name(s)
TMS
Other Intervention Name(s)
Magstim
Intervention Description
Real or Sham TMS will be given to the PD-MCI patient
Intervention Type
Device
Intervention Name(s)
Sham-TMS
Intervention Description
Real or Sham TMS will be given to the PD-MCI patient
Primary Outcome Measure Information:
Title
TMS stimulation applied to the left DLPFC has a quantifiable effect on cognition
Description
Changes in one or more of the five assessed brain domains at baseline and one day after stimulation will be measured by comparing the scores for the different neuropsychological tests.
The same neuropsychological assessment one month after TMS stimulation will show, if possible changes from one day after are longer lasting and can still be seen.
Time Frame
Neuropsychological Assessments: Baseline, one day after and one month after TMS stimulation
Secondary Outcome Measure Information:
Title
Change in structural grey and white matter in the brain at baseline compared to after TMS stimulation
Description
MRI analysis will measure any changes in cortical thickness (mm) or other structural changes in the brain after TMS or Sham-TMS stimulation
Time Frame
MRI: Baseline and two days after TMS stimulation
Title
Change in executive functioning measured as BOLD fMRI sequence
Description
The executive task, Wisconsin Card Sorting Task, will be performed in the scanner to measure the level of activation in the basal ganglia and the prefrontal cortex via BOLD functional MRI sequence to see changes after TMS stimulation compared to baseline.
Time Frame
MRI: Baseline and two days after TMS stimulation
Title
Change in levels of biomarkers of interest (alpha-synuclein and BDNF) in serum after TMS stimulation compared to baseline.
Description
Measure the concentration of alpha-synuclein and BDNF in serum at baseline and after TMS stimulation with the Meso Scale Discovery method. These assays are highly developed ELISA assays using electrochemiluminescence.
Time Frame
Blood draws: Baseline and two days after TMS stimulation
Title
Genotyping
Description
Analyze DNA for following genes: COMT, DAT1, MAPT, ApoE, GBA, CHCRA4, SNCA, BDNF These genes of interest will be correlated to changes in the neuropsychological assessments.
Time Frame
Blood draw for DNA analysis: Baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of idiopathic Parkinson's disease any stage
Mild Cognitive Behaviour confirmed through neuropsychological assessment
MRI Compatibility
Exclusion Criteria:
Alcohol-dependency
Severe psychiatric disorder, neurological disorder, epilepsy or stroke
General anaesthesia in the past six months
History of cerebrovascular disorders
Colour-blindness
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oury Monchi, PhD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Calgary, Department of Clinical Neurosciences
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N1
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
33408684
Citation
Lang S, Gan LS, Yoon EJ, Hanganu A, Kibreab M, Cheetham J, Hammer T, Kathol I, Sarna J, Martino D, Monchi O. Theta-Burst Stimulation for Cognitive Enhancement in Parkinson's Disease With Mild Cognitive Impairment: A Randomized, Double-Blind, Sham-Controlled Trial. Front Neurol. 2020 Dec 21;11:584374. doi: 10.3389/fneur.2020.584374. eCollection 2020.
Results Reference
derived
Learn more about this trial
Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease
We'll reach out to this number within 24 hrs